Sarepta Therapeutics Inc
NASDAQ: SRPT · HEALTHCARE · BIOTECHNOLOGY
Updated 2026-10-28
Sarepta Therapeutics Inc (SRPT) Stock Valuation Analysis
Fair value estimate, historical valuation range, and quality signals for SRPT.
Valued
Valuation reasonably reflects current fundamentals. Limited margin of safety at these levels.
SRPT historical valuation range
Where current P/E sits in SRPT's own 5Y range.
SRPT intrinsic value (DCF)
DCF-based fair value estimate vs current market price.
Standard discounted cash flow models produce unreliable output for unprofitable or near-breakeven companies. Revenue-based multiples such as P/S and EV/Sales, combined with the historical valuation position above, give a more reliable read for this stock.
Intrinsic value calculated using discounted cash flow (DCF) model based on projected free cash flows, discount rate, and terminal growth assumptions. A positive margin of safety indicates the current price is below estimated fair value, providing a cushion against estimation error.
SRPT valuation signals
Quick-read green flags, caution flags, and risks based on current metrics.
P/E Ratio — History
P/S Ratio — History
Current: 0.92x
Is SRPT overvalued in 2026?
Sarepta Therapeutics Inc (SRPT) currently trades at $19.32 per share with a market capitalization of $1,806,222,000.00. Based on our multi-factor framework, the stock trades at a fair valuation with a Smart Value Score of 50/100. This score blends growth quality, financial health, and price attractiveness into a single institutional-grade read.
SRPT currently has no meaningful P/E ratio, which typically signals that the company is unprofitable, near breakeven, or emerging from a loss-making period. With a P/S ratio of 0.9x, the market is valuing the company primarily on its revenue rather than its earnings.
Looking at its own history, SRPT is currently trading cheaper than 100% of the last 5Y on P/E. This places it in the 0th percentile of its historical range, a level that has historically coincided with attractive entry points.
A standard DCF model does not produce reliable output for SRPT under current conditions. For unprofitable or near-breakeven companies, revenue-based multiples such as EV/Sales and historical P/S percentile are more informative than intrinsic value calculations.
The Piotroski F-Score of 4/9 puts financial quality in a middling range, neither a standout strength nor an obvious red flag.
Bottom line: SRPT trades at a fair valuation on our framework, with a Smart Value Score of 50/100. The valuation is defensible but offers no obvious bargain. Patience or a better entry price may reward disciplined buyers.
Frequently asked questions
Is SRPT overvalued?
SRPT scores 50/100 on our Smart Value Score (Grade C), a mixed overall profile. A standard DCF is unreliable here given the profitability profile, so valuation leans on revenue-based measures like EV/Sales and the P/S percentile below.
What is SRPT's fair value?
A standard DCF is unreliable for SRPT given its current profitability profile. Revenue-based approaches like EV/Sales or the historical P/S percentile are more informative for this stock.
What P/E ratio does SRPT trade at?
SRPT does not have a meaningful P/E right now, usually a sign of unprofitability or an earnings transition. For unprofitable growth names, price-to-sales is the more useful gauge.
Is SRPT a buy based on valuation?
Our Smart Value rating for SRPT is Hold, from a Smart Value Score of 50/100 that blends growth, quality, and valuation. The profile is balanced and best suited to investors who already have a thesis. This is research to inform your decision, not personalized financial advice.
How does SRPT's valuation compare to its history?
On P/E, SRPT sits in the 0th percentile of its own 5Y range, historically cheap relative to where it has traded. A low percentile means today's multiple is near the bottom of its historical band.
What is SRPT's Smart Value Score?
SRPT's Smart Value Score is 50/100. It is a proprietary WallStSmart metric blending growth quality, financial health, and valuation into a single 0-100 read, and scores above 75 are rare, signaling strong multi-factor alignment.